News Genespire announces that GENE202 has been granted Orphan Drug Designation by the FDA and EC for the treatment of methylmalonic acidemia Gen 20, 2026leggi tutto Preclinical insights into dosing for first-in-human in vivo liver-directed gene therapy for MMA delivered in an oral presentation at the ASGCT Annual Meeting Mag 14, 2025leggi tutto Genespire announces oral presentation at the ASGCT Annual Meeting detailing preclinical insights into dosing for first-in-human in vivo liver-directed ISLV gene therapy for MMA Mag 8, 2025leggi tutto The AstraZeneca acquisition of EsoBiotec – important validation for Genespire’s lentiviral vector platform Mar 31, 2025leggi tutto Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic Set 25, 2024leggi tutto Genespire Presents Positive Preclinical Proof of Concept Data at the ASGCT Annual Meeting Mag 9, 2024leggi tutto Genespire Strengthens Management Team with Two Key Appointments Apr 5, 2021leggi tutto Genespire appoints Jörn Aldag as Chairman of the Board of Directors Lug 2, 2020leggi tutto Genespire and the San Raffaele Telethon Institute for Gene Therapyannounce publication in Nature Biotechnology on enhanced gene editingtechnique in hematopoietic stem cells Giu 2, 2020leggi tutto « Post precedenti
Genespire announces that GENE202 has been granted Orphan Drug Designation by the FDA and EC for the treatment of methylmalonic acidemia Gen 20, 2026leggi tutto
Preclinical insights into dosing for first-in-human in vivo liver-directed gene therapy for MMA delivered in an oral presentation at the ASGCT Annual Meeting Mag 14, 2025leggi tutto
Genespire announces oral presentation at the ASGCT Annual Meeting detailing preclinical insights into dosing for first-in-human in vivo liver-directed ISLV gene therapy for MMA Mag 8, 2025leggi tutto
The AstraZeneca acquisition of EsoBiotec – important validation for Genespire’s lentiviral vector platform Mar 31, 2025leggi tutto
Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic Set 25, 2024leggi tutto
Genespire Presents Positive Preclinical Proof of Concept Data at the ASGCT Annual Meeting Mag 9, 2024leggi tutto
Genespire and the San Raffaele Telethon Institute for Gene Therapyannounce publication in Nature Biotechnology on enhanced gene editingtechnique in hematopoietic stem cells Giu 2, 2020leggi tutto
